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The aim of this mnlticentre study was to analyse the long-term outcome of idiopathic membranopro­
liferative glomerulonephritis (MPGN) according to histological type and to the presence of C3 
nephritic factor. Fifty patients aged 2-14 years at the onset of the study were followed over 2 20 
years; 26 patients had MPGN type I, 17 had type II and 7 had type III. Treatment was variable. At the 
last observation, 30 patients had reached terminal and four pre-terminal renal failure. The median 
survival probability until renal death was 15.3, 8.7 and 15,9 years for disease types I, II and III 
respectively (difference between MPGN types I -I- III versus type II: p =  0.013). The presence of an 
initial nephrotic syndrome was associated with a more rapid progression (/; = 0.018). C3 nephritic 
factor was of no prognostic value. We conclude that the outcome of MPGN mainly depends on the 
histological type observed. □ C3 nephritic factor, membranoproliferative glomerulonephritis, renal 
failure
K Scharer, Division of Pediatric Nephrology, University Childrens Hospital, Im Neuenheimer Feld 150, 
69120 Heidelberg, Germany
Idiopathic membranoproliferative glomerulonephritis 
(M P G N ) is a primary glomerular disease that is a 
major cause o f renal failure in adolescents and young 
adults (1,2). Studies of glomerular line structure and of 
the mechanisms of complement activation have led to a 
distinction between three types o f M P G N  (3-5). The 
presence o f the C3 nephritic factor (C3 NcF) has been 
reported to be more or less specific for M P G N , and 
appears to influence its outcome (6, 7). Controversial 
issues exist on the pathogenesis and treatment of 
M P G N  (8).
In 1978, the Arbeitsgemeinschaft für Pädiatrische 
Nephrologie (APN ) started a multicentre study on 
children with biopsy-proven M P G N  (9). The aim of 
the study was to describe the clinical course in relation
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to histological findings in kidney biopsies and changes 
in serum complement, particularly with regard to the 
presence of C3 NeF. A short interim report on the 
clinical outcome and complement profiles o f the same 
patients reported here has been published previously 
(9). In the present paper we give an account of the 
long-term prognosis o f M P G N .
Patients and methods
From 1978 to 1982, 50 children with idiopathic 
M P G N  (27 F, 23M) were recruited in 17 paediatric 
nephrology centres. Twenty-nine patients had initial 
symptoms before 1978 for a median time of 3.0 
years. The age range was 2.2-13.7 (median 9.8) 
years at the apparent onset of M P G N . The patients 
were followed regulary one to two times a year over 
a period of 1.9-20.5 (median 11.4) years. All living 
patients were re-examined in 1992-1994 except five 
patients who were earlier lost to follow-up. At the 
last observation or at renal death the median age of 
the patients was 21.2 (range 5.4-29.1) years.
The diagnosis o f idiopathic M P G N  was made accord­
ing to the clinical presentation (proteinuria, nephrotic 
syndrome (NS), haematuria, hypertension) and to the 
findings of renal biopsies obtained by light microscopy,
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electron microscopy (including silver impregnation of 
ultra-thin sections) and immunofiuorescent studies. 
Biopsy material was reviewed centrally (H Thoenes, 
Department of Pathology, University of Mainz). Cri­
teria for the classification of M P G N  have been reported 
previously (3, 4). Secondary forms of M P G N  (8) were 
excluded. The median time from apparent onset o f the 
disease to renal biopsy was 0.4 (range 0.1-4.1) years, 
with 11 patients undergoing a biopsy procedure more 
than 1 year after onset.
Proteinuria in the range 150.1000 mg m “2/24 h (P +)
was regarded as mild, and proteinuria > 1000 mg m 2/ 
24 h was regarded as severe (nephrotic range) (P + +). 
NS was defined as the presence of severe proteinuria 
accompanied by serum albumin levels o f < 2 5 g l  l . 
Hypertension was defined as an arterial blood pressure 
> 140/90 m m H g or the application of antihypertensive 
agents. Chronic renal failure (CRF) corresponded to the 
presence of serum creatinine (SCR) levels that were 
regularly above 106 /¿moll“ 1 ( l ^ m g d l “ 1), and end- 
stage renal disease (ESRD ) corresponded to the start 
of regular dialysis therapy, except in one patient who 
had undergone a primary kidney transplant.
Patients’ sera were regularly screened centrally for the 
presence of C3 NeF using a cell-bound alternative C3- 
convertase (10).
The treatment was left to the discretion of each centre. 
Fifteen patients received prednisone for less than 6 
months and four patients received it for longer periods 
(usually on alternate days). Eight patients received 
cyclophosphamide and seven received various other 
immunosuppressive agents. Dipyridamole was given 
in 18 patients (four with NS at onset), usually over 
several years after diagnosis, in combination with 
acetylsalicylic acid (14 patients) and/or dieoumarol 
(four patients). Diuretics and/or various antihyperten­
sive agents were given to 32 patients. Eight patients 
received symptomatic therapy alone either in the form 
of diuretics and/or antihypertensive drugs. Four 
patients received no drugs at all.
Table I. Clinical presentation al apparent onset of MPGN.
Statistics
For data evaluation the Statistical Analysis System 
(SAS Institute, Cary, Nt\ USA) was used. The follow­
ing procedures were applied: P R O C  F R E Q  (Fisher’s 
exact test for 2 x 2  or larger tables) ( I I ) ,  PROC  PLOT  
(graphical presentation of percentages) (12) and P R O C  
L1FBTEST (survival analysis) (13).
At apparent onset 27 patients had clinical and labora­
tory signs of NS which was persistent in 7 and transient 
in 20 patients; 23 patients had mild proteinuria. Six 
patients with mild proteinuria later developed NS. 
Macroscopic hacinaturia initially occurred in 10
MPGN type
I 11 III Total
('/ =  26) (ii =  17) (n ~ 7) {n = 50)
Nephrotic syndrome (NS) 13 10 4 27
Mild proteinuria (P) 13 7 3 23
M aeroluiema tu ria (MM) 3 6 I 10
Microscopic haomaturiu (Mm) 16 5 30
Hypertension (Hy) y 4 2 15
Tahte 2. Distribution of C3 nephritic factor in serunt according to the
cliflerent histological types of MPGN.
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patients and hypertension was present in 15 cases. Urin­
ary findings are summarized in Table 1 according to the 
histological type o f M P G N . The distribution was simi­
lar in the different types o f  M P G N , except for macro- 
haematuria which was more frequent in type II (6/17) 
than in type I (3/26) (ns; Fisher's cxact test,;; =  0.069). 
C3 NeF activity was detected at various times during the 
follow-up in 30 patients (Table 2); it was more frequent 
in M P G N  type II than in types I or III (88% vs 42%; 
Fisher's cxact test, p =  0.003). Two C3-NcF-positive 
patients had partial lipodystrophy (both type II) and 
one had hemihypertrophy (type I).
The outcome of the disease at the last observation is 
summarized in Table 3. Thirty patients reached ESRD.
Tubk 3. Outcome of MPGN at the last observation.
MPGN type
Outcome I 11 111 'fotal
Fnd-sLage-renal disease (KSRD) 141* 13“ 3 30
(dialysis or transplantation) 
Time from onset to liSRD 15.3 «.7 15,0 I3.6h
(median in years) 
Pre-terminal renal failure o I 1 4
(CRF)
Proteinuria > 1 gm ~/24h 6 I 0 7
without CRF 
Proteinuria < I gm : /24 h 0 i++ 3 7
without CRF 
Cured 0 0 n
'1’otal 26 17 7 so
>M ^ i
Two patients died in each group.
*u)5% confidence interval* 9.3 1 5 .years.
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At the last observation four patients had CRF at 16-19 
years after apparent onset and 14 had proteinuria in the 
presence of normal SCR levels. Proteinuria was severe 
in 7 cases followed for 2-20 years, and mild in 7 
followed For 8-20 years. Two patients (both type I) 
were in complete remission. Four patients died after 
they had reached ESRD.
The probability of renal survival was analysed 
according to sex, initial presentation with or without 
NS, macrohaematuria, hypertension, histological type, 
presence of C3 NeF and the use of dipyridamole for 
treatment. By the Wilcoxon test, a significant associ­
ation of renal survival was found with the covariates 
initial proteinuria or NS (p =  0.016) and histological 
types I + III versus type II (/; =  0.021), but not with sex 
(p = 0.607), macrohaematuria (p =  0.356), hyper­
tension (p =  0.637), C3 NeF (p — 0,856) or use of 
dipyridamole (p =  0.117). O f 27 patients with an initial 
NS, 20 reached ESRD; two had CRF and five had 
proteinuria (one P++) at the last observation. In con­
trast, of 23 patients with mild proteinuria at onset only 
ten developed ESRD, two CRF , and 11 ended up with 
persistent proteinuria (six P++) or were cured. ESRD 
occured in 13 of 20 patients with a transient NS and in 
all with persistent NS (ns). In the six patients with initial 
proteinuria who later developed NS, ESRD was 
obligatory, whilst it occurred only in Four oF 17 patients 
with initial proteinuria without a change in NS (Fisher’s 
exact test, p =  0.002). Only two out of 11 patients with 
macrohaematuria did not reach CRF or ESRD (ns).
In the survival analysis the median time to reach 
ESRD after apparent onset of MPGN was 8.7 years in 
type II compared to 15.3 years in type I and 15.9 years in 
type III (Fig. 1). Ten years after onset renal survival was 
47% in type II compared to 64% in type I and 83% in 
type III. There was a statistically significant difference
Time from first SCR >106 ¿imol/l 
to ESRD (years)
Fig, 2. Renal survival probability from first SCR above 106 /¿moll 
(12m gd l'1) to ESRD in patients with idiopathic MPGN. (- 
MPGN types I and III; (• • *) MPGN type II.
)
in renal survival between types I 4- III versus type II 
(p =  0.013). However, the interval from the first SCR 
above 106 / iin o ir1 (1.2mgdl_1) to ESRD was not 
significantly different (p —  0.087), although after 3 
years there was a trend that patients with type II deterio­
rated more rapidly than those with type I or III disease 
(Fig. 2). The difference in renal survival from onset of 
the disease to ESRD in patients starting with NS against 
those with mild proteinuria was significant (p — 0.018, 
Fig. 3). However, when patients with NS at onset were 
analysed separately according to histological type, no
Time from outset to ESRD (years)
Fig. /. Renal survival probability from apparent onset of idiopathic 
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Fig. 3. Renal survival probability from apparent onset of disease to 
ESRD in patients with idiopathic MPGN. ( ) Pa lien is with NS at 
apparent onset of the disease; (> • •) patients without NS at apparent 
onset.
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significant difference was found in renal survival. ESRD 
developed in nine of the ten initial NS patients with type
II compared with 11 of 17 NS patients with type I or 
type III disease (Fisher’s exact test, p =  0.161).
Our analysis of the outcome in patients with and 
without detectable C3 NeF activity at any time revealed 
no significant difference. When C3-NeF-positive 
patients were analysed separately the difference between 
the outcome in type II versus types I -I- III remained 
significant: ESRD developed in 12 of 15 positive 
patients with type II against 6 of 15 positive patients 
with type I or III (Fisher's exact test, p = 0,03).
The outcome was also analysed according to treat­
ment with or without dipyridamole, combined or not 
with acetyl sa 1 icy lie acid or dicoumarol. There was no 
significant difference in renal survival between these two 
groups. However, in patients with mild proteinuria at 
onset the progression to CRF or ESRD was less 
frequent (2/12) when receiving dipyridamole than 
when the drug was not given (8/11) (Fisher’s exact 
test, p = 0 .01).
Discussion
In earlier reports an overall renal survival of 50% at 10 
years was calculated for children with MPGN (14, 15). 
Our results are slightly better. The long observation 
period of our patients and the statistical analysis used 
in this study enabled us to investigate more closeiy some 
factors influencing the prognosis. It was shown 
previously that patients who never develop NS survive 
longer than those with severe degrees of proteinuria 
(14 16). This observation was coniirmed for our popu- 
lation who in presence of initial NS reached ESRD 6.6 
years earlier than patients with mild proteinuria (Fig. 3). 
It seems that, with regard to the prognosis, initial clin­
ical manifestation is more important than the histo­
logical type of MPGN. The presence of NS seems also 
to be detrimental if it occurs during the later stage of the 
disease. In contrast to other studies we could not prove 
an influence of initial macrohaematuria (17) or initial 
hypertension (16),
We found a higher probability of renal survival in 
MPGN types I and III compared to type II, irrespective 
of the initial presence of a NS. For statistical reasons 
types I and III were combined in our analysis because 
their clinical and histological presentation is similar 
compared to type 11. From Fig. 1 it seems that type
III has a slightly better prognosis than type I.
Controversial opinions have been expressed regard­
ing the renal survival with different morphological 
types of MPGN. Cameron et al. (15) could not 
detect significant differences, although remissions 
occurred less frequently in patients with type II 
disease. Habib et al. (17) found a 50% renal survival 
at 18 years for type I and at 9 years for type II, values 
which, despite considerable advances in the symptomatic
treatment of CRF in the last 20 years, are similar to our 
data.
We confirmed that the C3 NeF in serum is more 
frequently found in type-II than in type-I patients 
(6, 15). We failed, however, to detect any significant 
difference in renal survival according to the presence of 
C3 NeF activity. This suggests that the C3 NeF status 
per se is of no prognostic value. This result is in contrast 
to a report (6) in which adult patients with C3 NeF 
activity deteriorated more rapidly. The discrepant 
results might be due to analytical differences in C3 
NeF screening which is poorly standardized,
Many drugs have been proposed for the treatment of 
MPGN, including corticosteroids (2, 16, 18-20), 
various immunosuppressive agents (8 , 15, 20-23) and 
anticoagulants with platelet inhibitors (22- 25). Most 
studies were uncontrolled. A randomized, double­
blind trial showed only a marginal effect of alternate- 
day prednisone treatment on the rate of deterioration of 
the glomerular filtration rate in children (19). Our study 
was not controlled and only a few patients were treated 
with steroids or immunosuppressive agents over longer 
periods. Eighteen children received anticoagulants and 
platelet inhibitors (24). We got the impression that in the 
presence of mild proteinuria this regimen delayed the 
progression to CRF or ESRD. However, recent data 
reported in the literature would deny any benefit of 
anticoagulants (24, 25).
In conclusion, the results of the study suggest that 
children suffering from M PGN continue to have an 
unfavourable late prognosis. The outcome is deter­
mined mainly by the initial presentation and by the 
histological type of the disease, while the presence of 
C3 NeF appears to play no role. There is a continuing 
need for new therapeutic options for MPGN,
1. White RMR, Mesangioeapillary glomerulonephritis. In: 
Edehnunn CM, editor. Pediatric kidney diseases, Boston: Little 
and Brown, 1902
2. Mclincry PT, Coutinho MJ. Membra noprolilenitive glomerulo­
nephritis. in: Hollidny M, Barratt TM, Avner IvlXeditors. Pedia­
tric nephrology, 3rd rev ed. Baltimore: Williams & V/ilk ins, IW
3. Anders D, Thoenes W. Basement membrane changes in membra* 
no proliferative glomerulonephritis: a light and electron micro­
scopic study. Virchows Arch [A] 14>75;3f>y:87- 109
4. Anders 10, Agricola B, Sippel M v Tluienes W. Basement mem­
brane changes in mem bra noproli feral ivc glomerulonephritis. 
ParL II: Characterization of a third type by silver impregnation 
of ultra thin sections. Virchows Arcli [A] 1S)77;376:1 19
5. Strife CT\ McEnery PT, McAdams A.L WesL CD. Membrano- 
proliferative glomerulonephritis with disruption of the glomerular 
basement membrane. Clin Nephrol 1077;7:65 72
6 . Sehena FI\ Pertosa G> Slanziale P, Vox U, Pceoraro C\ 
Andreticei VH. Biological significance of C3 nephritic factor in 
membranoproliferntive glomerulonephritis. Clin Nephrol 19S2; 
1H:240 - f t
7. Klein M, Poueell S, Arbus (IS, McGraw M, Ranee CP, Yoon ST 
el al. Characteristics of a benign subtype of dense deposit disease:
312 R Schwertz et til. ACTA IM'DFATR 85 (19%)
comparison with the progressive form of the disease. Clin Nephrol
1983;20:163-71
8 . Williams DG, Mesangiocapilhiry glomerulonephritis. In: 
Cameron S, Davison AM , Grunfeld J-P, Kerr P, Ritz E, editors. 
Oxford textbook of clinical nephrology, vol 1 Oxford: Oxford 
University Press, 1992
9. Anders D, for the Arbeitsgemeinschaft Padiatrischc Nephrologie. 
Cooperative long-term follow-up study in children with mem- 
bmnoproliferative glomerulonephritis (MPGN, three types). In: 
Murakami K, Kitagawa T, Yabuta K, Sekai T, editors. Recent 
advances in pediatric nephrology. Amsterdam: Exccrpta Medica, 
1987
10. Rother U. A new sreening test for C3 nephritis factor based on 
a stable bound convcrtase on sheep erythrocytes. J Immunol 
Methods 1982;51:101-7
1 L SAS/STAT user's guide, vol 1, ACECLUS-FREQ, Release 6.04 
edition. Cary, NC: SAS Institute Inc., 1990
12. SAS/GRAPH software, vol 2, Release 6 edition, Cary, NC: SAS 
Institute Inc., 1990
13. SAS/STAT user’s guide, vol 2, GLM-VARCOMP, Release 6.04 
edition, Cary, NC: SAS Institute Inc., 1990
14. Habib R, Kleinkneeht C, Gubler MC, Levy M. Idiopathic mem- 
branoproliferative glomerulonephritis in children. Report of 105 
cases, Clin Nephrol 1973;1:194-214
15. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, 
Chantler, C, et al. Idiopathic mesangioeapillary glomerulone­
phritis. Comparison of types I and II in childhood and adults 
and long-term prognosis. Am J Med 1983;74:175-92
16. Somers M, Kertesz S, Rosen S, Herrin J, Colvin R, Palacios de 
Carreta N, et al. Non-nephrotic children with membranopro­
liferative glomerulonephritis: Are steroids indicated? Pediatr 
Nephrol 1995;9:140-4
17. Habib R, Gubler M-C, Loirat C, Maiz B, Levy M. Dense deposit 
disease: a variant of membranoproliferative glomerulonephritis. 
Kidney Int 1975;7:204-14
18. Ford MD, Briscoe DM, Shanley PF, Lum GM. Childhood mem­
bra noproli Í era tive glomerulonephritis type I: limited steroid
therapy. Kidney Int 1992;41:1606-12
19. Tarshish P, Bernstein J, Tobin FN, Edelmann CM. Treatment of 
mesangioeapillary glomerulonephritis with alternate day pred­
nisone. A report of the international study of kidney disease in 
children. Pediatr Nephrol 1992;6:123-30
20. Bergstein JM, Andreoli SP. Response of type I membranopro- 
liferative glomerulonephritis to pulse methyl prednisolone and 
a 1 te r n a te- d a y p re dnisone therapy. Pediatr Nephrol 1995;9:269 71
21. Robson AM, Cole BR, Kienstre RA, Kissane JM, Alkjaersig N, 
Fletcher AP. Severe glomerulonephritis complicated by coagu­
lopathy: treatment with anticoagulant and immunosuppressive 
drugs. J Pediatr 1977;90:881-92
22. Chapman SJ, Cameron JS, Chantler C, Turner D. Treatment of 
mesangioeapillary glomerulonephritis in children with combined 
immunosuppression and anticoagulation. Arch Dis Child
1980;55:446-51
23. Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosup­
pressive treatment of membranoproliferative glomerulonephritis. 
Nephron 1994;67:59-65
24. Donadio JV. Membranoproliferative glomerulonephritis. In 
Schrier RW, Gottschalk CW, editors. Diseases of the kidney. 
Boston: Little and Brown, 1993
25. Schcna FP, Cameron JS. Treatment of proteinuric idiopathic 
glomerulonephritides in adults: a retrospective survey. Am J 
Med 1988;85:315-26
Received July 27, 1995. Accepted Oct. 12, 1995
